Related Experiment Video
Updated: Dec 7, 2025
03:17
Author Spotlight: Advancing Diabetes Research with Static Exercise Training in Mice
Published on: March 29, 2024
862
[Update: new forms of therapy for type-2-diabetes]
1Abteilung für Endokrinologie, Diabetologie und klinische Ernährung, Kantonsspital Luzern.
Therapeutische Umschau. Revue Therapeutique
|September 30, 2020
Summary
Newer type-2-diabetes therapies, including GLP-1-receptor agonists and SGLT-2-inhibitors, offer weight loss and cardiovascular benefits without hypoglycemia risk. Current guidelines recommend these for patients with cardiovascular disease or high risk.
Area of Science:
- Endocrinology
- Pharmacology
- Nephrology
Background:
- Type-2 diabetes treatment has fundamentally changed recently.
- Newer antidiabetic medications offer weight loss and no hypoglycemia risk.
- Cardiovascular outcome trials show benefits for specific drug classes.
Purpose of the Study:
- To review newer antidiabetic substances.
- To discuss updated therapy strategies for type-2 diabetes.
- To outline practical treatment regimens based on current guidelines.
Main Methods:
- Review of recent clinical trials and guidelines.
- Overview of dipeptidyl peptidase-IV (DPPIV)-inhibitors, GLP-1-receptor agonists, and SGLT-2 inhibitors.
- Discussion of therapeutic strategies for type-2 diabetes management.
Main Results:
- GLP-1-receptor agonists and SGLT-2 inhibitors demonstrate positive cardiovascular outcomes.
- SGLT-2 inhibitors show specific nephroprotective effects.
- Newer agents have no intrinsic risk of hypoglycemia and promote weight loss.
Conclusions:
- Modified therapy strategies prioritize GLP-1-receptor agonists and SGLT-2 inhibitors for high-risk patients.
- These medications are crucial for managing type-2 diabetes, cardiovascular health, and kidney protection.
- Current guidelines advocate for incorporating these agents into treatment plans.
Related Concept Videos
01:15Diabetes: Management and Pharmacotherapy
761
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
761
01:22Diabetes Mellitus: Type 2 and Gestational
4.1K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
4.1K
01:36Carbohydrate Metabolism
13.2K
Carbohydrates are polymers composed of molecules containing atoms of carbon, hydrogen and oxygen. One gram of carbohydrate can provide four kilo-calories of energy, which makes it the most efficient instant energy source.
Starch accounts for approximately 60% of the carbohydrates consumed by humans. Since amylase enzymes cannot function in the stomach's acidic environment, starch can only be digested in the mouth and small intestine. Simple sugars are found naturally in milk and fruits in...
Starch accounts for approximately 60% of the carbohydrates consumed by humans. Since amylase enzymes cannot function in the stomach's acidic environment, starch can only be digested in the mouth and small intestine. Simple sugars are found naturally in milk and fruits in...
13.2K
01:22Diabetes Mellitus: Overview and Type I Subtype
4.6K
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
4.6K
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
500
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
500
01:20Pathophysiology of Diabetes
2.8K
Diabetes mellitus is a chronic metabolic disorder characterized by hyperglycemia. The four categories of diabetes are type 1 diabetes, type 2 diabetes, other specific types of diabetes, and gestational diabetes.
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...
2.8K